Biogen Inc (BIIB) : Ashfield Capital Partners reduced its stake in Biogen Inc by 10.16% during the most recent quarter end. The investment management company now holds a total of 39,262 shares of Biogen Inc which is valued at $12,347,506 after selling 4,439 shares in Biogen Inc , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.Biogen Inc makes up approximately 0.94% of Ashfield Capital Partners’s portfolio.
Other Hedge Funds, Including , Allegis Investment Advisors boosted its stake in BIIB in the latest quarter, The investment management firm added 196 additional shares and now holds a total of 2,007 shares of Biogen Inc which is valued at $631,181. Biogen Inc makes up approx 0.30% of Allegis Investment Advisors’s portfolio.Palisades Hudson Asset Management reduced its stake in BIIB by selling 70 shares or 3.78% in the most recent quarter. The Hedge Fund company now holds 1,781 shares of BIIB which is valued at $562,725. Biogen Inc makes up approx 0.44% of Palisades Hudson Asset Management’s portfolio.Daiwa Securities Group boosted its stake in BIIB in the latest quarter, The investment management firm added 5,400 additional shares and now holds a total of 17,250 shares of Biogen Inc which is valued at $4,974,038. Biogen Inc makes up approx 0.03% of Daiwa Securities Group’s portfolio.Davis R M Inc reduced its stake in BIIB by selling 630 shares or 34.33% in the most recent quarter. The Hedge Fund company now holds 1,205 shares of BIIB which is valued at $315,108. Biogen Inc makes up approx 0.02% of Davis R M Inc’s portfolio.
Biogen Inc closed down -0.55 points or -0.18% at $313.39 with 9,29,774 shares getting traded on Monday. Post opening the session at $313.4, the shares hit an intraday low of $310.01 and an intraday high of $315.08 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Biogen Inc reported $5.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.52 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $4.69. The company had revenue of $2894.00 million for the quarter, compared to analysts expectations of $2790.65 million. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.22 EPS.
Many Wall Street Analysts have commented on Biogen Inc. Biogen Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016. Biogen Inc was Downgraded by Citigroup to ” Neutral” on Jun 7, 2016.
Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.